{{Drugbox
| IUPAC_name        = {(4''S'')-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
| image             = Letermovir skeletal.svg
| alt               = 
| caption           = 

<!-- Clinical data -->
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Investigational
| routes_of_administration = Oral

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 

<!-- Identifiers -->
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 45138674
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1H09Y5WO1F
| DrugBank          = 
| ChemSpiderID      = 26352849
| ChEMBL            = 1241951
| synonyms          = AIC246
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10801
<!-- Chemical data -->
| C=29 | H=28 | F=4 | N=4 | O=4
| molecular_weight  = 572.55 g/mol
| smiles = COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
| StdInChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
| StdInChIKey = FWYSMLBETOMXAG-QHCPKHFHSA-N
}}

'''萊莫維韋'''（Letermovir）是一種用於治療[[巨細胞病毒|巨細胞病毒]]感染的藥物。本藥物已經於[[骨髓移植|骨髓移植]]併發巨細胞感染的患者身上測試，且可能也對[[HIV|HIV]]感染或器官移植後等免疫功能不良的患者有相同療效<ref name="DAZ">{{cite news|url=http://www.deutsche-apotheker-zeitung.de/pharmazie/news/2011/09/02/neues-virostatikum-letermovir/5205.html|title=Neues Virostatikum Letermovir|date=2011-08-29|publisher=Deutsche Apothekerzeitung|language=de}}</ref>。

本品已被[[美国食品药品监督管理局|美國食品藥品監督管理局]]給予快速審查資格，也獲得[[欧洲药品管理局|歐洲藥品管理局]]的[[孤儿药|罕用藥]]資格<ref name="DAZ" />。 

本品由[[默克藥廠|默克有限公司]]（Merck & Co., Inc）以化合物「MK-8228」為名進行開發及研究<ref>{{cite web|url=http://www.clinicalleader.com/doc/merck-kicks-off-phase-study-of-cmv-drug-letermovir-0001|title=Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir|accessdate=8 Oct 2014|date=July 29, 2014|last=Masangkay|first=Estel Grace}}</ref>。


==參考文獻==
{{reflist}}

[[Category:三氟甲基化合物|Category:三氟甲基化合物]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:羧酸|Category:羧酸]]